{
    "nctId": "NCT04476485",
    "briefTitle": "Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy",
    "officialTitle": "A Newly Discovered Clinical Recurrence Predictor for High-risk Hormone Receptor-positive Breast Cancer: a Real Word Study",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 1000,
    "primaryOutcomeMeasure": "disease-free survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* early-stage invasive breast cancer positive for estrogen receptor and / or progesterone receptor is pathologically confirmed;\n* patients who have completed standard endocrine therapy for 5 years without recurrence and metastasis;\n* 18-70 years old;\n* patients with one of the following six manifestations: KI67 \u2265 30%; tumor size \\> 2 cm; positive lymph nodes; histological grade III; vascular cancer thrombus; HER-2 gene overexpression or amplification.\n\nExclusion Criteria:\n\n* with a history of other malignancies;\n* patients who have severe abnormalities in important organs, such as the heart, liver, and kidney or who cannot be tolerant to extended treatment due to poor constitution;\n* patients with severe osteoporosis or dyslipidemia, or those who cannot tolerate endocrine therapy ;\n* patients who have participated in other clinical trials.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}